Prevention and treatment of senile osteoporosis and hip fractures

Minerva Medica

Volumn 100, Issue 1, 2009, Pages 79-94

  Duque, G ^a,b   Demontiero, O ^a,b   Troen, B R ^c,d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b NEPEAN HOSPITAL   (Australia)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d Miami Veterans Affairs Healthcare System   (United States)

Author keywords

Fractures, bone; Hip fractures; Osteoporosis

Indexed keywords

ALENDRONIC ACID; CALCITONIN; CALCIUM; COLECALCIFEROL; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; VITAMIN D; ZOLEDRONIC ACID;

BONE DENSITY; BONE PAIN; CALCIUM INTAKE; CLINICAL TRIAL; DEMENTIA; DIARRHEA; DRUG DOSE COMPARISON; FALLING; FEVER; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; JAW OSTEONECROSIS; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NONHUMAN; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PREVALENCE; PRIMARY PREVENTION; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; SENILE OSTEOPOROSIS; UNSPECIFIED SIDE EFFECT; VITAMIN INTAKE;

EID: 66449125840     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. Duque G, Troen BR. Understanding the Mechanisms of Senile Osteoporosis: New Facts for a Major Geriatric Syndrome. J Am Geriatr Soc 2008;56:935-941
2. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005;115:3318-25. (Pubitemid 43121814)
3. Chan GK, Duque G. Age-related bone loss: old bone, new facts. Gerontology 2002;48:62-71. (Pubitemid 34195721)
4. National Osteoporosis Foundation (2002) America's bone health: the state of osteoporosis and low bone mass in our nation [internet]. [cited 2009 February 02]. Available at: http://www.nof.org/advocacy/prevalence/
5. Schneider EL, Guralnik JM. The aging of America. Impact on health care costs. JAMA 1990;(263):2335.
6. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007;22:465-475
7. Dennison E, Cole Z, Cooper C. Diagnosis and epidemiology of osteoporosis. Curr Opin Rheumatol 2005;(17):456-461
8. Burge RT. The cost of osteoporotic fractures in the UK: Projections for 2000-2020. Journal of Medical Economics 2001;(4):51.
9. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359:1761-1767
10. Friesendorff MV, Besjakov J, Åkesson K. Long-Term Survival and Fracture Risk After Hip Fracture: A 22-Year Follow-Up in Women. J Bone Miner Res 2008;23:1832-1841
11. Bhattacharyya T, Iorio R, Healy WL. Rate of and risk factors for acute inpatient mortality after orthopaedic surgery. J Bone Joint Surg Am 2002;84:562-572
12. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999;353:878-882 (Pubitemid 29126875)
13. Hamlet WP, Lieberman JR, Freedman EL, Dorey F, Fletcher A, Johnson EE. Influence of health status and the timing of surgery on mortality in hip fracture patients. Am J Orthop 1997;26:621-627
14. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK The components of excess mortality after hip fracture. Bone 2003;32:468-473 (Pubitemid 39665705)
15. Hannan EL, Magaziner J, Wang JJ, Eastwood EA, Silberzweig SB, Gilbert M et al. Mortality and locomotion 6 months after hospitalization for hip fracture: risk factors and risk-adjusted hospital outcomes. JAMA 2001;285:2736-2742
16. Koot VC, Peeters PH, de Jong JR, Clevers GJ, Van Der Werken C. Functional results after treatment of hip fracture: a multicentre, prospective study in 215 patients. Eur J Surg 2000;166:480-485 (Pubitemid 30399335)
17. Lewiecki EM. Update on bone density testing. Curr Osteoporos Rep 2005;3:136-142
18. Watts NB. Fundamentals and pitfalls of bone densitometry using dual-energy X-ray absorptiometry (DXA). Osteoporos Int 2004;15:847-854 (Pubitemid 39506450)
19. Järvinen TL, Sievänen H, Khan KM, Heinonen A, Kannus P. Shifting the focus in fracture prevention from osteoporosis to falls. BMJ 2008;336:124-126
20. Cummings SR, Karpf DB, Harris F et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs [Meta-analysis]. Am J Med 2002;112:281-289
21. Eastell R, Hannon RA, Garnero P, Campbell MJ, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis. J Bone Miner Res 2007;22:1656-60.
22. Watts NB, Cooper C, Lindsay R, Eastell R, Manhart MD, Barton IP et al. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom 2004;7:255-261
23. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 2002;17:1-10. (Pubitemid 33150990)
24. Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res 2006;21:1785-1790 (Pubitemid 46141234)
25. Wainwright SA, Marshall LM, Ensrud KE, Cauley JA, Black DM, Hillier TA et al. Study of osteoporotic fractures research group, hip fracture in women without osteoporosis. J Clin Endocrinol Metab 2005;90:2787-2793
26. Kanis JA, Borgstrom F, De Laet C, , Johansson H, Johnell O, Jonsson B et al. Assessment of fracture risk. Osteoporos Int 2005;16:581-589
27. Popp AW, Senn C, Franta O, Krieg MA, Perrelet R, Lippuner K. Tibial or hip BMD predict clinical fracture risk equally well: results from a prospective study in 700 elderly Swiss women. Osteoporos Int 2008 [Epub ahead of print].
28. Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007;18:1033-1046
29. Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen TV. Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int 2008;19:1431-1444
30. Faulkner KA, Cauley JA, Zmuda JM, Landsittel DP, Cummings SR, Studenski SA, Nevitt MC. Associations of Physical Function and Fall Frequency in Older Caucasian Women. J Am Geriatr Soc 2007 55(4):S31.
31. Montero-Odasso M, Schapira M, Soriano ER, Varela M, Kaplan R, Camera LA et al. Gait velocity as a single predictor of adverse events in healthy seniors aged 75 years and older. J Gerontol A Biol Sci Med Sci 2005;60:1304-1309
32. Tinetti ME, Performance-oriented assessment of mobility problems in elderly patients. J Am Geriatr Soc 1986;34:119-126 (Pubitemid 16159911)
33. Qaseem A, Vincenza S. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the american college of physicians. Ann Intern Med 2008;149:404-415
34. Boonen S, Dejaeger E, Vanderschueren D, Venken K, Bogaerts A, Verschueren S et al. Osteoporosis and osteoporotic fracture occurrence and prevention in the elderly: a geriatric perspective. Best Pract Res Clin Endocrinol Metab 2008;22:765-785
35. Schneider DL. Management of osteoporosis in geriatric populations. Curr Osteoporos Rep 2008;6:100-107
36. Cherniack EP, Levis S, Troen BR. Hypovitaminosis D: a widespread epidemic. Geriatrics 2008;63:24-30.
37. Roux C, Bischoff-Ferrari HA, Papapoulos SE, de Papp AE, West JA, Bouillon R. New insights into the role of vitamin D and calcium in osteoporosis management: an expert roundtable discussion. Curr Med Res Opin 2008;24:1363-1370
38. Ish-Shalom S, Segal E, Salganik T, Raz B, Bromberg IL, Vieth R. Comparison of daily, weekly, and monthly vitamin D3 in ethanol dosing protocols for two months in elderly hip fracture patients. J Clin Endocrinol Metab 2008;93:3430-3435
39. Bischoff-Ferrari HA, Rees JR, Grau MV, Barry E, Gui J, Baron JA. Effect of calcium supplementation on fracture risk: a double-blind randomized controlled trial. Am J Clin Nutr 2008;87:1945-1951
40. Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992;327:1637-1642
41. Chapuy MC, Pamphile R, Paris E, Kempf C, Schlichting M, Arnaud S et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip. fracture risk: the Decalvos II Study. Osteoporos Int 2002;13:257-264
42. Chapuy MC, Arlot ME, Delmans PD, Meunier PJ. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 1994;308:1081-1082 (Pubitemid 24124866)
43. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture Prevention with vitamin d supplementation a meta-analysis of randomized controlled trials. JAMA 2005;293:2257-2264 (Pubitemid 40629192)
44. Avenell A, Gillespie WJ, Gillespie LD, O'Connell DL. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and postmenopausal osteoporosis. Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.: CD000227. DOI: 10.1002/14651858.CD000227.pub2.
45. Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet. 2007 370(9588):657-666 (Pubitemid 47285316)
46. Minami A, Ishimura N, Sakamoto S, Takishita E, Mawatari K, Okada K et al. Vitamin D insufficiency impairs the effect of alendronate for the treatment of osteoporosis in postmenopausal women. J Bone Miner Res 2005;20(Suppl 1):S296.
47. Dawson-Hughes B. Serum 25-hydroxyvitamin D and functional outcomes in the elderly. Am J Clin Nutr 2008;88:537S-40S.
48. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2007;85:1586-91. Erratum in: Am J Clin Nutr 2008;87:794. (Pubitemid 46890428)
49. Bouillon R, Bischoff-Ferrari H, Willett W. Vitamin D and health: perspectives from mice and man. J Bone Miner Re. 2008;23:974-979
50. Duque G, Rivas D. Alendronate has an anabolic effect on bone through the differentiation of mesenchymal stem cells. J Bone Miner Res 2007;22:1603-1611
51. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-1541
52. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000;85:4118-4124
53. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-2082
54. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA et al. for the FLEX Research Group Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296:2927-2938
55. Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database of Systematic Reviews 2008;(1):Art.No.: CD001155.DOI:10.1002/14651858.CD001155.pub2.
56. Papapoulos SE, Quandt SA, Liberman UA, Hochberg MC, Thompson DE. Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int 2005;16:468-474
57. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C et al. Summary of metaanalysis of therapies for postmenopausal osteoporosis. Endocr Rev 2002;23:570-8.
58. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296:2927-2938
59. Wehren LE, Hosking D, Hochberg MC. Putting evidence-based medicine into clinical practice: comparing anti-resorptive agents for the treatment of osteoporosis. Curr Med Res Opin 2004;20:525-531 (Pubitemid 38525161)
60. Silverman SL, Watts NB. Effectiveness of bisphosphonates on non-vertebral and hip fractures in the first year of therapy: The risedronate and alendronate (REAL) cohort study Osteoporos Int 2007;18:25-34.
61. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of residronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-1352
62. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91.
63. McClung MR, Geusens P, Miller PD et al. Effect of Residronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;(344):333-340.
64. Cranney A, Tugwell P, Adachi J et al. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev. 2002;(23):517-523
65. Boonen S, Laan RF, Barton IP, Watts NB. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and metaanalyses of intention-to-treat studies. Osteoporos Int. 2005;(16): 1291-1298 (Pubitemid 41396959)
66. Wells G, Cranney A, Peterson J, J, Boucher M, Shea B, Robinson V et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database of Systematic Reviews. 2008;(1). Art. No.: CD004523. DOI:10.1002/14651858. CD004523.pub3.
67. The Cochrane Musculoskeletal Group [Homepage]. [cited 2009 February 02]. Available at: www.cochranemsk.org
68. Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S et al. Fosamax Actonel Comparison Trial Investigators. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 2005;20:141-151
69. Reid DM, Hosking D, Kendler D, Brandi ML, Wark JD, Marques-Neto JF et al. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International. Int J Clin Pract 2008;62;575-584
70. Cadarette SM, Katz JN. Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Ann Intern Med 2008;148:637-646
71. McClung MR. Bisphosphonates in osteoporosis: recent clinical experience. Expert Opin Pharmacother 2000;1:225-238
72. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-1199
73. van den Boogaard CHA, Breekveldt-Postma NS, Borggreve SE, Goettsch WG, Herings RM. et al. Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study. Curr Med Res Opin 2006;22:1757-1764
74. Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453-1460 (Pubitemid 41368578)
75. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004;48:271-287 (Pubitemid 38781153)
76. Penning-van Beest FJA, Goettsch WG, Erkens JA, Herings RM. Determinants of persistence with Bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther 2006;28:236-242 (Pubitemid 44287822)
77. Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005;80:856-861 (Pubitemid 40911458)
78. Penning-van Beest FJA, Erkens JA, Olson M, Herings RMC. Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int 2008;19:511-517
79. Chesnut III CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A et al. for the Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19: 1241-1249
80. Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE Study. J Bone Miner Res 2005;20: 1315-1322
81. Reginster J-Y, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006;65:654-661
82. Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one year results from the Dosing Intravenous Administration Study. Arthritis Rheum 2006;54:1838-1846
83. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-1822
84. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C et al. Zoledronic acid and clinical features and mortality after hip fracture. N Engl J Med 2007;357:1799-1809
85. Seeman E, Delmas PD. Reconstructing the skeleton with intermittent parathyroid hormone. Trends Endocrinol Metab 2001;12:281-283 (Pubitemid 33714219)
86. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY et al. Effect of Parathyroid Hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-1441
87. Boonen S, Marin F, Mellstrom D, Xie L, Desaiah D, Krege JH et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc 2006;54:782-789
88. Troen BR. Osteoporosis in older people: A tale of two studies (and three treatments). JAGS. 2006;54:853-855 (Pubitemid 44030211)
89. Mosekilde L. Vitamin D and the elderly. Clin Endocrinol (Oxf) 2005;62:265-281
90. Holick MF. The vitamin D epidemic and its health consequences. J Nutr 2005;135:2739S-48S. (Pubitemid 43156624)
91. Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R et al. Estimates of optimal vitamin D status. Osteoporos Int 2005;16:713-716
92. Tashjian AH Jr, Goltzman D. On the interpretation of rat carcinogenicity studies for human PTH(1-34) and human PTH(1-84). J Bone Miner Res 2008;236:803-811
93. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-468
94. Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C et al. Strontium ranelate reduces the risk of non-vertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90:2816-2822
95. O'Donnell S, Cranney A, Wells GA, Adachi J, Reginster JY. Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.:CD005326. DOI: 10.1002/14651858.CD005326.pub3.
96. Mosekilde L, Vestergaard P, Langdahl B. Fracture prevention in postmenopausal women. BMJ Clin Evid 2008;01:1109.
97. Chestnut CH III, Silverman S, Andriano K, Genant H, Gimona A, Harris S et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000;109:267-276
98. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials. BMC Musculoskelet Disord 2001;2:7. (Pubitemid 38904591)
99. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of non-vertebral fractures: a meta-analysis of randomized trials. JAMA 2001;285:2891-2897 (Pubitemid 32537354)
100. Delmas P. Treatment of postmenopausal osteoporosis. Lancet 2002;359:2018-2026 (Pubitemid 34663722)
101. Ettinger B, Black DM, Mitlak BH , Knickerbocker RK, Nickelsen T, Genant HK et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282:637-45.
102. Writing group for the women's health initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333
103. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative Randomized Controlled Trial. JAMA 2004;291:1701-1712